Medical Device News Magazine

FX Solutions Receives FDA 510(k) Clearance for Lateralized & Augmented Glenoid Baseplates

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

FX Solutions received 510k clearance for its lateralized and augmented glenoid baseplates. With these additions, FX brings ten additional glenoid baseplate options to the market.

 

The glenoid baseplates are available in 24mm options with additional lateralization, augments, and lateralized augments. The lateralized glenoid baseplates are available with a central screw or central post option. The augmented glenoid baseplates are available with the central screw option only.

The Humelock glenoid baseplate is a 24mm round baseplate available in four options: baseplate with a central cannulated post, baseplate with a central screw (with seven 4.5mm central screw length options from 8-20mm in 2mm increments), lateralized baseplate with +3mm or +6mm added, and augmented baseplate with 7.5° (3mm thick) or 15° (6.5mm thick) half-wedge added, +0, +3mm, or +6mm lateralized. Lateralization and augmentation are added under the flat surface of the baseplate and above the post.

“As we continue to grow the FX portfolio, we evolve ever closer to providing a tailor-made approach for surgeons using our portfolio. They may be able to adapt the system to the patient rather than the patient to our system. This clearance of the lateralized and augmented glenoid baseplates is truly significant for our portfolio and the treatment of patients’ shoulders,” said Baptiste Martin, CEO of FX Shoulder USA.

With the launch of the lateralized glenoid baseplates FX will include upgrades of their current instrumentation to include a first-to-market and completely unique patent-pending trialing system for the reverse glenoid construct. This features a monobloc trial consisting of the glenosphere and lateralized glenoid baseplate together to better replicate the feel of the definitive implants.

FX continues to innovate based upon surgeon feedback and market trends with a focus exclusively on shoulder arthroplasty with the goal of becoming a global market leader in this segment.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”